Sweden · Delayed Price · Currency is SEK Flerie AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong financing, raising SEK 208 million and boosting NAV to SEK 3.7 billion. The investment ratio reached 2.33x, with significant R&D progress and a completed Lipum merger, despite challenging market conditions.
Fiscal Year 2025
-
Q4 saw a 14% NAV decline to SEK 3.4 billion, driven by write-downs in key holdings and strategic divestment of the LP segment. Management remains optimistic, citing strong clinical progress, robust cash reserves, and a focus on direct investments for long-term value creation.
-
NAV declined to SEK 3.9 billion in Q3, impacted by write-downs and share redemptions. Key portfolio milestones included successful capital raises, a merger, and new strategic partnerships, while market conditions showed early signs of recovery.
-
Celebrating its IPO anniversary, the company reported a SEK 4.1 billion NAV, strong cash position, and portfolio growth driven by clinical and commercial stage investments. Outperformed key indices despite a tough macro environment, with innovative M&A and capital management strategies.
-
NAV declined to SEK 3.947 billion in Q1, driven by negative fair value and FX impacts, but strong cash reserves and proactive portfolio management support resilience. Key actions included a full write-off of Provell, divestment of A3P at a premium, and a proposed Toleranzia merger.
Fiscal Year 2024
-
NAV ended Q4 2024 at SEK 4.2 billion, down 1.5% sequentially, with strong co-investor leverage and significant new investments in AnaCardio, Chromafora, and Nanologica. Product development segment faced valuation declines, but cash position remains robust and a redemption program is in place.
-
NAV per share declined 2.7% in Q3 to SEK 54.59, with portfolio fair value at SEK 2.993 billion and net loss of SEK 117 million. Significant cash reserves and a new share redemption scheme support liquidity, while key clinical milestones and syndication efforts are expected to drive future value.
-
NAV rose to SEK 4.4 billion after a successful Nasdaq listing and capital raise, with a diversified portfolio of 29 companies and strong liquidity exceeding SEK 1 billion. Adjusted NAV per share increased 2.1%, and key clinical milestones were achieved across several holdings.